Table 2.
PD-L1 expressions at diagnosis in subgroups
| The Percentages of PD-L1 positive blasts (mean ± S.ED) | p | |
|---|---|---|
| t(8,21) | ||
| Positive (n:7) | 4.44 ± 5.22 1.97 | 0.282 |
| Negative (n:31) | 2.18 ± 2.82 0.51 | |
| inv(16) | ||
| Positive (n:2) | 0.92 ± 0.67 0.47 | 0.629 |
| Negative (n:30) | 2.89 ± 3.62 0.66 | |
| t(15,17) | ||
| Positive (n:13) | 2.47 ± 3.88 1.08 | 0.09 |
| Negative (n:69) | 3.38 ± 4.56 0.55 | |
| t(9,11) | ||
| Positive (n:3) | 2.3 ± 2.65 1.53 | 0.934 |
| Negative (n:32) | 3.51 ± 5.57 0.98 | |
| NPM1mut | ||
| Positive (n:3) | 5.43 ± 4.91 2.84 | 0.448 |
| Negative (n:12) | 2.96 ± 3.7 1.07 | |
| FLT3-ITD | ||
| Positive (n:5) | 3.35 ± 3.92 1.75 | 0.981 |
| Negative (n:28) | 3.83 ± 6 1.13 | |
| AML with myelodysplasia-related changes (n:9) | 2.96 ± 2.99 1.0 | 0.73 |
| AML without myelodysplasia-related changes (n:77) | 3.25 ± 4.5 0.51 | |
| AML with minimal differentiation (n:6) | 5.15 ± 3.77 1.54 | 0.408 |
| AML without maturation (n:8) | 2.71 ± 3.52 1.25 | |
| AML with maturation (n:5) | 2.02 ± 0.82 0.37 | |
| Acute myelomonocytic leukemia (n:12) | 1.94 ± 2.06 0.59 | |
| Acute monoblastic/monocytic leukemia (n:14) | 3.73 ± 7.28 1.95 | |
| Lymphadenopathy | ||
| Exist (n:11) | 6.34 ± 7.98 2.41 | 0.092 |
| Not exist (n:75) | 2.77 ± 3.39 0.39 | |
| Splenomegaly | ||
| Exist (n:15) | 3.84 ± 7.44 1.92 | 0.357 |
| Not exist (n:71) | 3.09 ± 3.44 0.41 | |
| Extramedullary involvement | ||
| Exist (n:4) | 4.08 ± 2.59 1.30 | 0.136 |
| Not exist (n:82) | 3.15 ± 4.42 0.49 | |
| CRP | ||
| > ULT (n:59) | 3.54 ± 4.84 0.63 | 0.564 |
| < ULT (n:27) | 2.53 ± 3 0.58 |
ULT upper limit of normal